Capstone Therapeutics to Present at Biotech Showcase 2011
06 Janvier 2011 - 10:52PM
Capstone Therapeutics (Nasdaq:CAPS) is scheduled
to make a presentation at the Biotech Showcase 2011, Parc 55
Wyndham San Francisco – Union Square, 55 Cyril Magnin Street, San
Francisco on Monday, January 10, 2011 at 3:15pm PST. Dana B.
Shinbaum, Vice President, Business Development will provide an
overview and discuss the Company's current operating environment
and business strategy.
The presentation may be accessed through the Company's website
at www.capstonethx.com under "Investors".
About Capstone Therapeutics
Capstone Therapeutics is a biotechnology company committed to
developing a pipeline of novel therapeutic peptides aimed at
helping patients with under-served medical conditions. The
Company is focused on development and commercialization of two
product platforms: AZX100 and Chrysalin (rusalatide acetate or
TP508).
AZX100 is a novel synthetic 24-amino acid peptide, one of a new
class of compounds in the field of smooth muscle relaxation and
fibrosis. Based on its demonstrated safety and signals of
efficacy in Phase 2 clinical trials, as well as its safety and
effectiveness in pre-clinical models, AZX100 is currently being
evaluated for commercially significant medical applications such as
the prevention or reduction of hypertrophic and keloid scarring and
treatment of pulmonary fibrosis. Capstone has an exclusive
worldwide license to AZX100.
Chrysalin, the Company's novel synthetic 23-amino acid peptide,
has been proven in multiple pre-clinical and clinical models to
stimulate cellular events leading to angiogenesis,
revascularization, and repair of dermal and musculoskeletal
tissues. It is currently being evaluated in disorders that
involve vascular endothelial dysfunction, such as acute myocardial
infarction and chronic myocardial ischemia. The Company owns
certain worldwide rights to Chrysalin.
Capstone's corporate headquarters are in Tempe,
Arizona. For more information, please visit the Company's
website: www.capstonethx.com.
The Capstone Therapeutics logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5429
Statements in this press release or otherwise attributable to
Capstone regarding our business that are not historical facts are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements, which include the timing and acceptability of FDA
filings and the efficacy and marketability of potential products,
involve risks and uncertainties that could cause actual results to
differ materially from predicted results. These risks include:
delays in obtaining or inability to obtain FDA, institutional
review board or other regulatory approvals of pre-clinical or
clinical testing; unfavorable outcomes in our pre-clinical and
clinical testing; the development by others of competing
technologies and therapeutics that may have greater efficacy or
lower cost; delays in obtaining or inability to obtain FDA or other
necessary regulatory approval of our products; our inability to
successfully and cost effectively develop or outsource
manufacturing and marketing of any products we are able to bring to
market; changes in FDA or other regulations that affect our ability
to obtain regulatory approval of our products, increase our
manufacturing costs or limit our ability to market our product;
effects of the Capstone Stockholder Put Right on our stock price,
liquidity or our ability to continue operations; effects on our
stock price and liquidity if we are unable to meet the requirements
for continued listing on the Nasdaq Capital Market; our need for
additional capital in the future to fund the continued development
of our product candidates; and other factors discussed in our Form
10-K for the fiscal year ended December 31, 2009, and other
documents we file with the Securities and Exchange Commission.
Editor's Note: This press release is also
available under the Investors section of the Company's website at
www.capstonethx.com.
CONTACT: Karen Struck, Investor Relations
(602) 286-5250
kstruck@capstonethx.com
Lauren Glaser - The Trout Group
(415) 392-3310
lglaser@troutgroup.com
Capstone Therapeutics Corp (MM) (NASDAQ:CAPS)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Capstone Therapeutics Corp (MM) (NASDAQ:CAPS)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024